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INTRODUCTION 
Cancers cause over 800,000 deaths in the EU each year and  account for 25% of all 
deaths.  Mortality and incidence rates vary considerably by country : for example, both 
are comparatively low in Spain in relation to melanoma of the  skin,  although,  as  in 
other parts of  the EU, mortality rates from that cancer are increasing.  By contrast, in 
neighbouring  Portugal  mortality  from  cancer  of the  stomach  is  much  higher  than 
elsewhere in the EU,. although rates are  now falling  (albeit  slowly)  as  in other EU 
Member States. 
Within the EU, the treatment of  cancer has ceased to be separated into the interests of 
surgeons,  chemotherapists and radiotherapists,  and  has become an  int~grated clinical 
discipline.  Further improvements in cancer therapy will require an integration of the 
fundamental and clinical approaches to research, with particular attention to building of 
necessary interactions between cellular,  molecular  and  developmental  genetics with 
oncology  and  epidemiology.  This  will  permit  the  development  of new  biological 
insights into the underlying causes of cancer and the ways in which they interact with 
normal cellular processes.  Greater understanding of the ways in which cell  division 
and  proliferation are controlled,  and  the isolation of new genetic and  environmental 
factors which determine and interact with controls, will in tum allow the development 
of new approaches to prevention, early detection and treatment.  The study of  host-
tumour interactions in the context of escape from immune response,  and of somatic 
gene therapy could have a major impact on cancer treatment. 
The approaches of  cellular and molecular genetics are most powerful if combined with 
strong epidemiological studies, which are essential for identifying the interplay between 
the  environmental  and  genetic  components  determining  carcinogenesis. 
Epidemiological studies are best conducted ori a multinational collaborative basis, and 
should have a high priority at' the European level. 
Clinical research aims at improvement in both diagnosis and treatment for cancers.  In 
general, the earlier cancers are diagnosed,  the better the prognosis for the treatment. 
There are  still  striking discrepancies for treatment outcomes in  different  regions  or 
between countries, .  and while some of this may  be  due to fundamental biological or 
genetic differences, much is due to unequal availability of  best diagnosis or treatment; 
the  aim  should  be  to  bring  the  same  high  standard  of quality  care  to  all  patients. 
Therefore,  in  addition  to  more  fundamental  research,  clinical  research  also  has  to 
facilitate the transition of the new opportunities into clinical utility, with emphasis on 
usefulness,  accessibility and feasibility  of application to patients with cancer in daily 
practice. 
A m  the context of the BIO:MED  2 programme,  research is  conducted  on molecular 
mechanisms. of  tumorigenesis and metastasis, on the control of  normal cellular growth, 
. differentiation  and  death;  and  abnormalities  which  C8Jl  alter these to predispose to 
cancer,  and  on  specific  anti-tumour  immune ,responses  and  possibilities  for  early 
detection.,  Furthermore,  research  is  undertaken- to  support_  the  effectiveness  of -
systemic  treatment,  the· therapeutic  ratio  of radiotherapy  and  the  field  of ballistic 
selectivity.  Finally the quality of  life as a parameter fot;' treatment assessment· is also 
addressed withinthe programn1e. 
I  .  . 
The pace of discovery, within the EU, of scientific aspects of cancer research and of 
developments in the clinical field  are  so rapid that it is  sometimes ·difficult to keep 
abreast.  This brief overview attempts-to highlight some of  the advances ·in the field, as 
part of  the BIOMED programme funded research and specific results. due to the co-
operative spirit established by the scientific community.  It is particularly worth noting 
the financial investment of 3  5 million ECU in the current programme, has acted as a 
catalyst  in attrActing  a  large number  of Member  States  funded  research  teams  in 
pooling their collective knowledge base.  \  · 
The  secretarial  support  of Mrs.  Jo  Trines  in  the  preparation  of this  document  is 
acknowledged. 
Dr. S.S. Baig 
European Commission 
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S.S. BAIG/jt- August 1997  Page 1 Title.: Molecular ~echanisms of extracellular proteolysis in cancer invasion and 
-metastasis.  A step towards a rational anti-metastatic therapy. 
Contract N° :  BMH4-CT9_6-00l7 
Period : 31/05/96 - 30/05/99  Total EC Contribution : ECU 950,000 
Degradation of  the extracellular matrix and basement membranes plays a crucial role in 
cancer invasion and  metastasis.  This  degradation is accomplished  by the concerted 
action  of several  extracellular  proteolytic .enzyme-systems.  The  objective  of the 
· present  proposal  is  ~o  contribute  to  a  clarification·· of molecular  mechanisms  of 
extracellular  proteolysis  by  defining  the  interaction  between  the  various  enzyme 
systems' in cancer invasion, the ultimate goal being to create the basis for a rational 
''approach to anti-invasive and  anti-metastatic therapy, which may result in increased 
survival and quality of  life for cancer patients. 
The most important of the proteolytic enzymes involved in cancer invasion belong to 
the  families  of  matrix  metalloproteinases  (several  types  of  collagenases  and 
stromelysins) and serene proteinases (the plasminogen activator uP  A).  The activity of 
these enzymes is finely regulated by proenzyme activation, specific inhibitors and cell 
surface receptors.  These extracellular proteolytic enzyme systems are also involved in 
matrix  degradation  in  non-neoplaStic  tissue  remodelling  processes.  The  main  . 
difference between the neoplastic and non-neoplastic processes appears in this respect 
to be in_ the regulation of  the expression of  the yarious components. 
Many  of these  enzym~ systems  are  very  well  characterised.  The  partners  in  the 
-proposed project are all among the internationally leading in the field  of extracellular 
protoolysis and  cancer,  and· have typically contributed by in depth studies of one or 
two of  the enzymes or enzyme systems.  Recent studies, in the partners' laboratories 
and  elsewhere,  on the biochemistry and  expression of  components of these enzyme 
systems· indicate that there is strong interaction and cooperativity between the systems, 
and particularly results obtained by targeted gene disruption in transgenic mice suggest 
that there is a functional overlap between the individual systems. 
Inhibition  of  matrix degrading enzyme systems is an attractive ·new approach to anti-
invasive  and  anti-metastatic therapy,  and some  drugs  with this  effect  are  currently 
being investigated in clinical trials.  The functional overlap between individual enzyme 
systems,  discussed. above  however  indicates  that  such  a  therapy,  in  order  to  .b~ 
effective, requires that two or more of  the systems are inhibited~  In order to provide a 
rational basis for  such a combined therapy,  it is  necessary that the interactions and 
functional  overlaps  between the individual· proteolytic  systems  are  exactly  defined. 
The objectives of the present- proposal are to combine the expertise of the individual 
partners in the individual enzyme systems in a concerted effort to obtain this goal. 
I 
These  objectives  comply  precisely  with  the  objectives ·of the  BIOMED  2  work 
programme 4.1.1., as to define molecular mechanisms of cancer metastasis.  It will be 
achieved  by  : · analysis  of- the  molecular  m~chanisms controlling  co-ordinate · gene 
expression ·of components· of extracellular proteolytic enzyme systems during invasion 
·  and  by  biochemical- analysis  of  interaction  between  matrix  proteinase.  systems. 
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cancer invasion and metastasis will be carried out as well as evaluation of prognostic 
and  therapeutic  aspects  of interaction  between  extracellular  proteolytic  enzyme 
systems in cancer.  A search for novel molecules mvolved in extracellular proteolysis in 
cancer invasion and metastasis is proposed. 
Keywords  :  Cancer.  Invasion.  Metastasis.  Proteolytic  enzymes.  Molecular 
mechanisms.  Therapy .. Matrix  metalloproteases.  Plasminogen 
activators. 
Project Leader : 
Prof. K. Danoe 
Finsen Laboratory 
Rigshospitalet 
Strandboulevarden 49 
DK - 2100 Copenhagen 
TEL: 45-35-455615 
FAX: 45- 31-385450 
with participation of  : 
Prof. F. Blasi 
DffiiT, Ospedale S. Raffaele 
Via Olgettina 60 
I- 20188 Milano 
TEL : 39-2-26434832 
FAX : 39 2-26434744 
Prof. C.  Lopez~Otin 
Dept. de Biologia& Funcional 
Universidad de Ovido 
Facultad de Medicina 
E- 3  3  006 Ovidod 
TEL: 34-85-103571 
FAX: 34-85-103564 
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Prof. P. Chambon 
Laboratoire de Genetique Moleculaire 
Des Eucaryoutes du C.N.R.S. 
Faculte de Medecine 
11, rue Humann 
F- 67085 Strasbourg Cedex 
TEL : 33-3-88653425 
FAX: 33-3-.88653201 
Prof. G. Muiphy 
Cell & Molecular Biology Department 
Strangeways Research Laboratory 
Wort's Causeway 
GB- Cambridge CB1  4RN 
TEL: 44-12-23243231 
FAX: 44-12-23411609 
Page3 Prof K  .. Tryggvason  Prof. P. Basset 
Department of  Medical Biochemistry  Laboratoire de Genetique Moleculaire 
and Biophysics  Des Eucaryoutes: du C.N.R.S 
Karolinska lnstituttet  lnstitut de Chimie Biqlogique 
S- 17  ~ 77 Stockholm  Factulte de Medecine 
II,  ·rue Humann 
F- 67085 StrasbourgCedex 
TEL: 46-8-7287720  TEL : 33-3-88653425 . 
FAX: 46-8-337462  FAX : 33-3-8865320I 
Marie-Christine Rio  Dr. V. Dive 
Laboratoire de Genetique Moleculai~e  Departement d'Ingenierie et d'Etudes des 
Des Eucaryoutes du C.N.R.S ·  proteines 
Institut de Chimie Biologique  Laboratoire structure des proteines en 
Faculte de Medecine  .  solution 
Il, rue_ Humann  Bat. 152 -.C.E. Saclay 
F- 67085 Strasbourg Cedex  F- 9II9I Gif Sur Yvette ·Cedex 
TEL·: 33-3-88653425  TEL: 33-1-69083585 
FAX': 33-3-88653201  FAX: 33-I-6908907I 
S.S. BAIG/jt- August 1997  Page4 Title :  Molecular mechanisms of angiogenesis associated to cancer progression : 
targets  for  new  diagnostic  tools  and  for  new  anticancer  therapeutic 
approaches 
Contract N° :  BMH4-CT96-0669 
Period : l/7/96 - 30/06/99  Total EC Contribution : ECU 550,000 
Angiogenesis is crucial in the progression of solid  tumours and  in the formation of 
metastases. 
Although tumours  1-~ mm diameter can receive nutrients by diffusion, further growth 
depends on the formation of  a network of  new vessels.  Furthermore these new vessels 
are target for invading tumour cells and represent the best way to spreading in other 
organs.  Many clinical studies support this model and have concluded, that the number 
and  the  density  of vessels  in  different  human  cancers  directly  correlate  with their 
potential  to  progress  and  produce  metastases.  In  animal  models,  angiogenesis 
inhibitors gave favourable  results on cancer progression.  However,  there are some 
conflicting  data,  such  as  the  observation  that  not  all  angiogenic  tumours  produce 
metastases,  or that metastases develop  many  years  after the  appearance  of a well-
vascularised tumour. 
These observations indicate that a change in the phenotype of endothelial cells in the 
tumour is essential for the progression of  the disease, rather than a simple increase of 
number of  vessels. 
The  general  objective  of this  proposal  is  to  develop  new  instruments  (diagnostic, 
therapeutic, experimental) on tumour angiogenesis to improve the information required 
for the prognosis and  search new therapeutic strategies for the treatment of cancer. 
These tools (mAbs to vascular cells, to angiogenic factors and their receptors, cDNAs, 
animal  models,  antagonist  molecules)  will  be  developed  from  the  molecular  and 
biological knowledge's obtained by the different partners.  The availability of more 
sophisticated instruments and their evaluation in animal models and in selected series 
of patients will  provide an invaluable  asset to public health  and  European industry 
interested in the development of diagnostic and therapeutic agents for cancer disease. 
Therefore the identification of an endothelial  phenotype more favourable  to cancer 
progression, the development of  Abs to this phenotype, or to molecules involved in it 
their expression (Section .1  and 2) will be a central focus of  this project. 
Section 2 will study molecules which regulate angiogenesis and their mechanisms of 
action.  The aim of  this section is. to produce specific mutants with antagonistic activity 
or molecules which interfere with signal transduction pathways. 
Section 3 will develop new animal models to test the reagents prepared by sections 1 
and  2  and  to  define  different  angiogenic  profiles.  The  diagnostic  and therapeutic 
usefulness of  tools developed by section 1 and 2 will be tested in clinical trials (Section 
4).  . 
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diagnostic and therapeurl:c strategies concerning solid· tumours and to favour a better. 
management of  this disease.  . 
Project Leader : 
Prof. F. Bussolino 
Dipartimento Genetica, Biologia e Chimica Medica 
Vta Santena 5 bis 
1- 10126 Torino 
TEL: 39-11-6706684 
FAX: 39-11-6634563 
E-Mail : U236PESCA@CSI.IT 
with participation of : 
· Dr. M. Grandi 
Dept. ofExperimental Oncology and 
Preclinical Research 
Business ·Area .Oncology Immunology 
Via Giovanni XXIII, 23 
I- 20014 Nerviano 
TEL : 39-331-583321 
FAX: 39-331-583398 
Dr. M. Ziche 
Dept. of  Preclinical and Clinical 
Pharmacology 
Viale Morgagni 65 
1- 50134 Firenze 
TEL : 39-55-4237457 
FAX: 39-55-4361613 
Dr. H. Weich 
Department of  Gene Expression 
Mascheroder Weg f 
D- 3  8124 Braunschweig. Lower Saxony. 
TEL: 49-531-6181445 
FAX: 49-531-6181458 
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Dr. L. Claesson-Welsh 
LudWig Institute for Cancer Research 
Biomedical Centre 
P.O.Box 595 
Husargatan 3 
S~ 75124 Uppsala 
TEL: 46-18-551688 
FAX : 46-18-506867 
E-Mail : Lena~  Welsh@_LICR uu. se 
Dr. M.E. Maragoudakis 
Dept. ofPharmacology 
University ofPatras Medical School 
GR- 26500 Patras, Achaia 
TEL: 30-61-997638 
FAX: 30-61-994720 
Prof K.K. Alitalo-
University. of  Helsinki 
Haartman Institute 
P.O.Box21 
Haarmaninkatu 3 
SF- 0014 Helsinki 
TEL : 3  58-0-4346434 
FAX: 358-0-4346448 
E-Mail: Kari.Alitalo_@}!elsinki.FI 
Page6 Dr. M.G. Lampugnani 
Laboratory of  Vascular Biology 
Via Eritrea 62 
1- 20157 Milano 
TEL: 39-2-390141 ext 421 
FAX: 39-2-3546277 
E-Mail: 
Lampugnani@IRFMN.:MNEGR1.IT 
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Dr. A.L. Harris 
Imperial Cancer Research Fund 
Institute of  Molecular Medicine 
John Radcliffe Hospital 
University of  Oxford 
GB- Headington Oxford, OX3 9DU 
TEL: 44-1865-222408 
FAX: 44-1865-222431 
Page7 Title :  Receptor Tyrosine Kinase Signalling in Human cancer 
Contract  N° :  BMH4-CT96-0814 
Period : 1/8/96 - 3tn  /99  Total EC Contribution: ECU 1,000,000 
· Signalling  cascades  triggered  by  receptor  tyrosine  kinases  (RTKs)  are  frequently 
activated in human cancer.  To comprehend the role ofRTKs in tumours and devise 
strategies to intercede with their function,. detailed understanding of their mechanisms 
of action including ligand regulation and activation of cytoplasmic signal transducers, 
is required. 
This proposal focuses on the ErbB  and RET subfamilies ·of RTK.s  based upon· their 
· established involvement in prevalent types of human cancer.  Members· of the. ErbB 
RTK family  including EGFR,  ErbB~ and ErbB3,  are involved in human tumours by 
overexertion and constitutive receptor activation.  While autocrine stimulation of the 
EGFR in tumours has been established, the role of  natural ligands for the related ErbB 
receptors remains  elusive.  RET .  which  encodes  a RTK lacking  a known ligand,  is 
activated  by  structural  abnormalities  as  a  dominant  transforming  gene  in  various 
tumour types. 
To characterise ligand-receptor interactions relevant to malignancy, we will attempt to 
identify and isolate novel ligands regulating the actJvity  <;>f ErbB2,  ErbB3  and RET. 
Among known ligands, the role of  HRG on ErbB2, ErbB3 and EtbB4 activity will be 
determined in mod.el systems. 
Furthermore,  the  function  of membrane-anchored  forms  of  TGF  and  HRG will  be 
analysed,  including  possible  intrinsic  signalling  properties  associated  with  their 
cytoplasmic  domains.  Known  ligand--receptor  interactions  will  be  exploited  to 
specifically target tumour cells overexpressing ErbB  family  receptors in vitro and in 
vivo  using  cytotoxic' T  lymphocytes with recombinantly  engineered  T  cell  receptor 
components.  · 
Mechanisms  of receptor heterodimerisation  including  ligand-independent  activation 
will be determined for ErbB2 and ErbB3 synergy, whereas the activating potential of 
novel  mutations  in  the  ErbB2  juxtamembrane  region  will  be  evaluated  for  ErbB2-
signalling properties.  · 
Pathophysiologically relevant model systems will be established to measure ErbB .and 
RET  receptor function.  Reversion  of neoplastic  phenotypes  induced  by  MEN2A, 
MEN2B and mutated ErbB2, will be attempted by use of mutation-specific antisense 
oligonucleotides.  In ·the  case  of ·activated  RET  alleles,  this  approach  will  be 
complemented by investigating the potential of  certain Hirschsprung alleles to function 
as  dominant-negatives.  At  the  substrate  level,  research  is  focused  on targets  of 
ffiitogenic control relevant for human cancer.  Thus,  substrates in ErbB receptors and 
RET  pathways  segregating  with  increased  transforming  potential  are  of partic-ular 
interest  including  those  shared  between  RET  and  ErbB2  as  well  as  substrates 
specifically  associat~d  with  signal  transduction  by  RET  -MEN2B,  ErbB2-ErbB3  . 
heterodimers and point-mutated ErbB2.  Moreover, among a battery of  tyrosine kinase 
S.S. BAIG/jt- August 1997  PageS substrates  analysed,  she  and  eps8  are frequently  tyrosine  phosphorylated  in human 
tumours  projecting  their  role  as  universal  targets  for  tyrosine  kinases  activated  in 
human tumours. 
To expand the mechanistic understanding of  eps8 and she phosphorylation in tumours, 
functional interactions between both substrates will be investigated, and target proteins 
in the ·signalling cascade will be characterised.  The physiologic role of eps8 will be 
investigated by gene targeting in mice.  To facilitate  rapid identification of tumours 
with activated  tyrosine  kinases that would  be  amenable  for  therapeutic  approaches 
involving  tyrosine  kinase  inhibitors,  screening  tests  based  upon  she  and  eps8 
phosphorylation will  ~e developed.  Furthermore, this approach will provide the basis 
for  the  identification  of novel  tyrosine  kinases  selected  on  the  basis  of their 
involvement in human neoplasia. 
Keywords :  Oncogenes/Growth Factors/Phosphorylation/Substrates/Function/ 
Tumour Markers/Diagnosis/Therapy 
Project Leader : 
Pier Paolo Di Fiore (PPDF) 
Dept. of  Experimental Oncology, Division of  Signal Transduction 
lEO, European Institute of  Oncology 
Via Ripamonti 435 
I- 20141 Milano 
TEL : 39-2-574891 
FAX : 39-2-57489208 
with participation of  : 
Pier Giuseppe Pelicci (PGP) 
Istituto di Medicina Interna a Scienze 
Ohcologiche 
University of  Perugia, Policlinico 
Monteluce 
Via Brunamonti 
I- 06100 Perugia 
TEL : 39-75-5783255 
FAX: 39-75-5726264 
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Matthias H. Kraus (MK) 
Dept. ofExperimental Oncology, Section 
of  Receptor Pharmacology 
lEO, .E~ropean Institute of  Oncology 
Via Ripamonti 43 5 
I- 20141 Milano 
TEL : 39~2-574891 
FAX : 39-2-57489208 
Page9 . Christer Betsholtz (CB) 
Dept. of  Medical Biochemistry 
Institute of  Medical Biochemistry and 
Microbiology 
University of  Goteborg 
Medicinaregatan 9A 
S- 413 90 Goteborg 
TEL: 46-31-7733460 
FAX: 46-31-416108 
Atanasio Pandiella {AP) 
lnstituto de Microbiologia Bioquimica 
Cortsejo Superior de Investigaciones 
Cientificas 
Avenida del campo charro s/n 
E- Salamanca 37007 ·  .. 
TEL: 34-23-120561 
FAX : 34-23-267970 
Bernd Groner (BG) 
Klinik fur Tumourbiologie 
Breisacher Strasse 117 
D-79106 Freiburg i.Br 
TEL: 49-761-2061600 
FAX : 49-761-2061599 
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Mahvash Tavassoli {MT . 
University of  Sussex at Brighton 
School of  Biological Sciences 
Biology Bldg 
GB- Palmer, Brighton BN1 9QG 
TEL: 44-273-606755 
FAX : 44-273-678433 
·Massimo Santoro (MS) 
Dipartimento di Biologia  e. Patologia 
Cellulare e Molecolare 
University of  Naples Federico IT 
Via Sergio Pansini 5 
I- 80131 Napoli 
TEL : 39-81-7463056 
FAX: 39-81~7463037 
.· 
Page 10 Title :  Mammalian Chromoso~e  Stability and Cancers 
Contract N° :  BMH4-CT96-0894 
Period : 1/6/96 - 31/5/99 ·  Total EC Contribution : ECU 300,000 
The karyotypes of  cancer cells usually differ structurally and numerically from those of 
untransformed cells.  The differences are of central importance in the development of 
cancer but there is little understanding of their molecular bases.  The overall objective 
of our  proposal  is  to  develop  an  experimental  approach  to  the  analysis  of the 
mechanisms leading tc;>  some of  the chromosome abnormalities in cancer cells. 
Changes in chromosome number are likely to arise as result of errors in chromo.some 
segregation but the mechanism of chromosome segregation is  poorly understood in 
human  cells.  One  important  stumbling  block  to  the  systematic  study  of human 
chromosome  segregation is  that the identity  of the DNA sequence  responsible  for 
chromosome segregation ; the centrometric DNA has  not been identified.  The first  , 
objective  of our  programme  is  therefore  to  identify  the  functionally  significant 
centrometric DNA on a human chromosome. 
The  events  leading  to  deletions  and  gene  amplifications  in  tumour  cells  are  not 
understood however many observations made primarily by laboratories participating in 
this project (Paris,  Pavia)  indicate that double  strand breaks  play  a key  role in  the 
initiation of the amplification process and the formation of interstitial deletions.  The 
second objective of our programme is. to test the idea that double strand breakage is 
the key initiating event of  both types of  events. 
Activation of telomerase  is  now thought to play  a key  role  in the development  of 
cancer cells.  It  has therefore been suggested that inactivation of  telomerase would be a 
useful therapeutic approach.  The third objective of our programme is to test this idea 
by inducibly removing a telomere from a supernumerary mammalian chromosome and 
then examining the consequences for the chromosome and for the cell. 
Keywords : Centromere: telomere: double strand break: amplification: ere: 1-Sce-1. 
Project Leader: 
Pr. Michelle Debatisse-Buttin 
Institut Pasteur 
Unite de Genetique Somatique (URA CNRS 1960) 
25 rue du Dr. Roux 
F-75724 Paris Cedex 15 
TEL : 33-1-45688571 
FAX: 33-1-40613171 
E-Mail: mdebat@pasteur.fr 
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Pr. Elena Giulotto 
Universita' di Pavia 
Dipartimento di Genetica e Microbiologia 
Via Abbhltegrasso 207 · 
1-27100 Pavia· 
TEL : 39-382-505541 
FAX : 39-382-528496 
E-Mail:  iulotto  i  v  en.uni  v.it 
Dr. Manuel Valdivia 
Universidad de Cadiz 
Facultad de Ciencias 
Bioquimica y Biologia Molecular 
Apartido num. 40 
E- 11510 Puerto Real - Cadiz 
TEL : 34-56-830363 
FAX.: 34-56-834924 
E-Mail: manuel.valdivia  uca.es 
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Dr. Chiara Mondello 
Consiglio Nazionale Biochimica ed 
Evoluzionistica  .  · 
Via Abbiategrasso 207 
I- 27100 Pavia 
TEL :·39-382  .. 546329 
F~  :·39-382-422286 
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Dr. William Brown 
University of  Oxford 
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GB- Oxford OX1  3QU · 
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FAX: 44-865-275283 
E-Mail: wrab  bioch.ox.ac.uk 
Page 12 Title :  Effect of  transforming growth factor .6 on proto-oncogenes, tumour 
suppressor genes and cell cycle regulators : growth arrest versus apoptosis 
Contract No.: BMH4-CT-96-0995 
Period : l/l/96 - 31/12/99  Total EC Contribution : ECU 650,000 
Regulation of normal development and  tissue function is  the product of a balanced 
interplay between ·the mechanisms that regulate cell  division,  differentiation and  cell 
death.  Whereas  the  molecular  mechanisms  leading  to  cell  growth  and  their 
contribution to cell  transformation  have  been  extensively  explored  in  the  last  two 
decades,  much  less  is  known about the mechanisms  that inhibit  cell  growth,  most 
particularly in function of the adhesion status of the cell.  Furthermore, simultaneous 
activation  of the  growth  stimulatory  and  growth inhibitory  programmes  may  raise 
cellular conflict leading to cell death, both in normal as well as in tumour cells.  The 
overall aim  of this integrated proposal is  to define  the factors  which modulate key 
genes in the control of  cell cycle arrest and cell death.  The proto-oncogene c-myc and 
the tumour suppresser -gene p5  3 have been shown to be major players in the control of 
normal cell proliferation and the development of  malignancies.  Activation of  c-myc in 
quiescent cells is sufficient for induction of  DNA synthesis whereas, activation of  p53 
prevents  entry of cycling  cells  into  S phase,  but  also. renders  them  susceptible  to 
apoptosis.  Recent evidence suggests that extra-cellular matrix plays a protective role 
against  apoptosis.  Interestingly,  one of the  key  cell  cycle  regulators  of the  G 1/S 
transit,  cyclin  A  has  an  expression  which  is  strongly  induced  by  c-myc,  but  also 
dependent upon cell anchorage.  TGF  B,  a pleiotropicytokine that negatively regulates 
cell growth of mainly  epithelial cells,  induces a subset of the immediate early genes, 
notably  Jun B,  and  represses  some  of the  cell  cycle  regulators,  such  as  cyclin  A,  · 
through a signal transduction cascade which is  presently almost completely obscure. 
However,  whereas  growth  factors  stimulate  the  expression  of  extra-cellular 
metalloproteinases  collagenase  and  stromelysin,  TGF  B inhibits  their  expression  and 
could thus interfere with apoptosis. 
We plan to study TGFB  t:eceptor. signalling as well as the effect of  TGFB  on c-myc-
induced  cyclin  A  expression,  DNA  synthesis  and  apoptosis  in  p53+/+  and  p53-/-
contexts.  The regulation of  the expression and the interplay of  the selected players : c-
myc,  Jun  B  and  cyclin  A  will  be- analysed  at  both  the  transcriptional  and  post-
transcriptional  levels.  In  the  latter  we  will  investigate  changes  in  sub-cellular 
localisation  of both  c-myc  and  cyclin  A  mRNAs,  and  investigate  changes  in  the 
mRNA-cytoskeleton interactions and localisation in response to TGF  B. 
Keywords:  Oncogenes, tumour suppressers, TGF.B,  cyclins,  cell adhesion,  TGFB 
receptors. 
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Contract N° :  BMH4-CT96-0047 
. Period : 1/5/96 - 30/4/99  Total EC Contribution : ECU 400,000 
Amo1,1g the ·hundreds of protein kinases knoWn to date, protein kinase CK2 has been 
shown to act as an essential component for cell survival.  Compelling evidence strongly  · 
supports that CK2 is involved in the regulation of cell proliferation.  CK2 activity is 
increased  in  tumour  cells  and  its  catalytic  subunit  may  act  as  an  oncogene,  as 
suggested by a  recen~ observation in transgenic mice.  However understanding of its 
cellular functions at the molecular level remains elusive. 
The present project aims at an understanding of  CK2 functions related to proliferation 
in normal  and ·cancer  cells,  with  a  concerted  approach  combining  complementary 
expertise's, with the major objectives as follows : 
1..  Understand  the  structural  and  functional  organisation  of CK2  that  governs  its 
activity, its regulation and its specificity.  This conducted using is complementary 
approaches, including a set of  kinase mutants and should result in the development 
of  new possibilities to manipulate CK2' functions in living cells. 
2. Identify the CK2 subunit genes and develop methods to probe their activity· in living 
cells and to manipulate the expression of  the kinase or its subunits in cancer cells. 
3. Unravel the cellular proteins which are targets of  CK2 in vivo, by using the double 
hyb~d system in yeast.  Comparative patterns of CK2 target proteins in normal, 
cancer cells and human tumours should sheet light on the specific behaviour of  CK.2. 
in tranSformed cells and its possible role in oncogenesis. 
4.  Understand the role of CK2 in the regulation of specific cell functions related to 
growth  control  and  cancer  (I)  organisation  of the  cytoskeleton  .and  neurite 
formation; (II) regulation of  topoisomeraseii and of  topo-II dependent resistance to 
anticancer  agents;  (III)  cell  response  to  the  growth  factor  FGF-2  and  rRNA 
synthesis regulation; (IV) role in the regulation of  the p53 protein functions as a cell 
cycle sUppressor and a cell apoptosis inducer in response to anticancer agents. 
5. Examine the status of  CK.2 (gene expression, molecular organisation and activity) in 
cancer cells and in frequent human tumours in Europe (i.e.  colorectal and  breast 
cancers).  In  this  context,  the  kinase  may  emerge  as  a  potential  prognostic 
parameter of value in patient management as  well  as  a potential target for drug 
therapy.  · 
· The present project represents a long waited· opportunity for the partners· to associate 
their interest and potential in a concerted task force.  This common endeavour should 
shed light on the implication of an ubiquitous although still mysterious protein kinase 
in basic regulation processes.· related to cell  growth and  neoplasia  and may  suggest 
related new strategies in cancer therapy. 
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molecular  events  involved  in  TNF-R1  and  Fas  I  AP0-1  apoptotic 
signalling 
Contract N°:  BMH4-CT96-0300 
Period : 1/09/96 - 31/08/99  Total EC Contribution : ECU 800,000 
. 
Aim of the project is the definition of the molecular requirements for the generation 
and  intracellular  transmission  of the  apoptotic  signal  from  surface  receptors  in 
transformed  cells.  _As  surface  receptor-mediated  apoptosis  induction  is  a  key 
mechanism exploited by immune effect cells to eliminate cancer cells,  understanding 
the biochemical nature of  the apoptotic signal is of  major relevance in cancer biology. 
The model we are using in the human  system is  represented by  two highly  related 
receptors, widely expressed on a variety of  normal and transformed cells,  the tumour 
necrosis factor receptor type 1 (TNF-Rl) and the Fas/AP0-1 receptor.  Crosslinking 
of TNF-R1  and Fas/AP0-1 by their specific ligands triggers a cascade of still largely 
undefined events, eventually leading to cellular apoptosis.  TNF-R1 and Fas/  AP0-1 are 
trimeric receptors which share extended structural homology, including a cytoplasmic 
region which has been named "death domain", as deletions or mutations within it result 
in the inability by the respective ligands to grigger apoptosis. 
Structural similarities both in the extracellular and  in the intracellular portion of the 
two receptors suggest similar mechanisms for the generation of the apoptotic signal, 
however differences  may  exist in the complexity of its  fine  regulation  and  control, 
which may be relevant for the specialisation of the death signal in different cell types. 
Our goal is to define the mechanisms for signal generation and propagation from the 
two receptors, identifying common central relays as well as unique control features of 
each  apoptotic  pathway.  We  will  address  receptor  structural  requirements  for 
productive  lingandlreceptor  interactions,  with  particular  emphasis  on  the  role  of 
alternatively spliced isoforms of  the Fas/  AP0-1 receptor in signal control.  Moreover, 
the  function  of death  domains  in  the  generation  of the  apoptotic  signal  will  be 
investigated,  specifically  by  searching  for  cytosolic  death  domain-like  molecules. 
Membrane  modifications  following  TNF-R1  and  Fas/AP0-1  crosslinking  and  their 
relevance for the propagation of the death signal will  be investigated by  measuring 
different  phospholipases  and  sphingomyelinases  activities  and  identifying  relevant 
downstream  targets.  We  will  therefore  study  how  relevant  diffusible  second 
messengers can activate potential distal targets, like interleukin-1  converting enzyme 
(ICE)  and  homologues,  as  well  as  reactive oxygen intermediates  (ROI),  potentially 
involved in  mediating the  effector phase of the response.  Finally,  the role  of bcl-2 
family  members,  key  players  in  the  control  of the  apoptotic  response,  will  be 
addressed. 
Defining  the  molecular  steps  responsible  for  TNF-Rl  and  Fas/AP0-1  induced 
apoptosis will reveal potential targets for anti-apoptotic strategies adopted by cancer 
cells to survive.  Uncover such strategies has potential relevance for both diagnosis and 
selective therapy of  tumours. 
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Page20 Title :  Novel  biological  systems  to  study the role  of single  oncoproteins  and 
tumour suppressors and their co-operation in leukaemogenesis 
Contract N° :  BMB4-CT96-1355 
Period : 1/4/96-31/3/99  Total EC CQntribution : ECU 400,000 
Human leukaemias are associated with identified genetic alterations including recurrent 
chromosomal translocations which lead to the synthesis of  novel fusion proteins or to 
the  ectopic  or  enhanced  expression  of normal  proteins  and  deletion  and  point 
mutations which result  in  loss  of function  of tumour  suppressor genes.  Although 
considerable progress has  been made  in  the identification of genes  associated with 
specific leukae~as and the way their expression is altered, much less is know on how 
single  genetic  alterations  contribute  to  leukaemic  development ·and  how  dominant 
oncogenes  and  recessive  tumour  suppressor  genes  cooperate  to  generate  the  full 
leukaemic phenotype.  We propose to use and further develop new cellular models to 
analyse how oncoproteins and tumour suppressors which are known to be involved in 
human leukaemias alter the proliferation, survival and differentiation control of  primary 
hematopoietic progenitors in tissue culture.  Fusion proteins involved in preleukaemic 
states like myeloid  dysplastic  syndromes  (MDS),  in  chronic myelogenous leukaemia 
(Cl\1L)  and  in  acute leukaemias of both the  myeloid  (AML)  and  lymphoid  (ALL) 
lineage's will be considered.  Specifically,  we will  analyse the properties of CMML-
associated Tel-PDGFRB, of C:ML-associated BCR-ABL and of several oncoproteins 
associated with AML including PlVIL-RARa, 'DEK-CAN, TLS-ERG as well as AMLI 
and :MLL fusion proteins. 
Very few genetics alterations are known to be implicated in MD S.  A major effort will 
be put in the identification of  novel genetic lesions specific to MDS and in the study of 
the activity of  the corresponding genes in hematopoietic progenitors. 
The cellular models we propose to use are also ideally suited to investigate how known 
tumour suppressor like p53  or candidate suppressor genes like ERF co-operate with 
oncoproteins  to  deregulate  the growth and  differentiation control of hematopoietic 
progenitors. 
To validate the results  obtaind in tissue  culture,  we will  develop  a  complementary 
approach in which ES  cells  will  be  genetically  modified  to express  specific  human 
oncoproteins as  combinations  thereof  These  cells  will  be  used  to  create  chime~c 
animals in which leukaemia development can be monitored. 
Description of the phenotypes associated with the expression of single  oncoproteins 
and tumour suppressors or combinations thereof in primary progenitors paves the way 
to  develop  a  screening  assay  for  pharmacological  compounds  interfering  with  the 
function of  these proteins. 
Keywords : Leukaemia/Hematopoietic  progenitors!ES  cells/Oncogenes/Tumour 
suppressor genes/Multi-step carcinogenesis. 
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Page 22 Title: The role of the E2F/DP genes in control of cell proliferation and 
oncogenesis 
Contract N° :  BMH4-CT96-1529 
Period : 1/7/96 30/6/99  Total EC Contribution: ECU 1,150,000 
The aim of  this proposal is to analyse the role of  the recently discovered transcription 
factors  of the E2F  and  DP gene families  in  the control of cell  proliferation and  in 
tilmourgenesis.  In mammalian cells, ordered progression through the individual phases 
of  the cell cycle is regulated by check-point control mechanisms, which ascertain that 
only ·normal  cells  will  replicate,  and  therefore  are  essential  for  the  maintenance  of 
genetic stability.  Loss of check-point control predisposes mammalian cells to cancer, 
emphasising the critical role of  cell cycle regulators for neoplastic disease.  Many genes 
implicated  in  cell  cycle  regulation  are  controlled  by  a  group  of heterodimeric 
transcription factors, composed of  proteins encoded by the E2F and DP gene families, 
respectively.  Thus,  tight  regulation  of E2F/DP  activity  may  play  a  key-role  in 
oncogenesis. 
In a first step, it is planned to identify and characterise the main cellular target genes 
controlled by the E2F/DP family  of transcription  fact~rs.  In  s~veral model  systems 
based  on synchronised cultured  cells,  a thorough· analysis of cell  cycle regulation of 
gene expression through E2F/DP proteins will be performed; particular attention will 
be paid to the question whether differences can be found between E2F sites present in 
distinct target genes,  or whether differential timing of E2F  -driven gene expression is 
determined  by  complex regulatory  elements,  involving  other DNA binding  proteins 
besides E2F.  To understand regulation ofE2F/DP activity, the expression of  different 
E2F and DP genes during the cell cycle and in different tissues will be analysed.  In 
addition,  we  will  analyse  the  role  of  post-translational  modification,  e.g. 
phosphorylation of  E2F  /DP proteins, and their interaction with other cellular proteins, 
including the products of oncogenes and tumour suppressor genes.  Furthermore, the 
consequences of over-expression of different E2F/DP genes in various cell types will 
be studied, to establish the oncogenic potential of individual family members, alone or 
in combination with other gene products.  These studies should provide an integrated 
view  of transcriptional  regulation  during  the  cell  cycle  and  cell  differentiation,  and 
allow  us  to  design  novel  strategies  to  unravel  the  role  of the  E2F/DP  regulatory 
network for growth control in normal and tumour cells. 
In  a  second  step,  we  intend  to  directly  address  the  role  of E2F/DP  genes  in 
tumourgenesis: it was shown recently that major cell cycle regulatory genes, including 
various cyclins,  cdks and  their inhibitors,  are  altered in  a variety  of human  cancers. 
However, changes in the structure or expression of  the E2F/DP genes in tumours were 
not reported.  To address this question, a series of clinical specimens will be screened 
for genetic alterations in the gene encoding E2F-1  through E2F-5  and DP-1  through 
DP-3.  Furthermore,  we  will  establish  a  transgenic  mouse  model  to· study  the 
involvement ofE2F/DP genes in human cancer, including T-celllymphoma. 
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Contract N° :  BMB4-CT96-0090 
Period·: 1/1/96 - 30/12/99  Total EC Contribution : ECU 500,000 
Tumour suppressor genes act as recessive determinants of  cancer.  It is recently known 
· that  various  actin-associated  cytoskeletal  proteins  and  structural  components  of 
intercellular junctions are encoded by,  or are related to products of  tumour suppressor 
genes. , Very little is. known of  how tumour suppressor molecules associate with or 
function atthe cortic~ membrane skeleton and/or specialised junction domains.  To 
understand  the  molecular  events  governing  tumour  suppressor  activity,  extensive 
molecular cell biology· studies have to be implemented.  This is the major objective of 
our proposal. 
As a choice of  tumour suppressor, we will study schwannomin.  Schwannomin is the 
product  of the  NF2  gene  which,  when  mutated  at  the  germline  leve~  causes 
,  neurofibromatosis ··type  2,  a  tumour  susceptibility  disease  predisposing  mainly  to 
meningiomas  and  schwannomas.  Schwannomin,  together  with  ezrin,  radixin,  and 
moesin, comprise the ERM family of  membrane  cytoskeletallinke~ proteins.  To define 
the specific  activity of schwannomin requires  an  understanding  of the role ··of each 
member of  the ERM family.  Moreover, since ERM proteins are involved in adhesion 
events that are essential for the control of  epithelial cell differentiation and growth, we 
Will also investigate how the assembly of  junctional membrane domains, such as tight 
and adherents junctions,. is regulated. 
To  understand  how these various  sub-membranous .protein  complexes  function  will 
require  us  to  analyse  the  multiple  interactions  that  occur. between  the  numerous 
components involved.  Especially, we will investigate how changes in interactions can 
mediate  tumourogenic  potential  since  activation  of membrane  receptors  (notably 
HGF/SF  receptor,  the  product  of the  c-met  proto-oncogene)  can  initiate  signal 
transaction via ERM and junctional proteins leading to junction destabilisation,  actin 
microfilament reorganisation and loss of  control of  cell proliferation. 
We will utilise different developmental and  cellular fl¥ldels,  including Dictyostelium, 
Xenopus embryos,  mouse preimplaotation embryos,  genetically engirieered  cell lines, 
as well as sophisticated in vitro. biophysical assays to study the pattern of expression 
and  mode  of interaction  of tumour  suppressor  molecules.  Modem  molecular 
techniques,  using  probes generated and  shared  by  participating laboratories,  will be 
used in these experimental systems to modulate, inhibit,  delete, rescue or overexposes 
tumour suppressor proteins, and thereby to gain novel insight into how they function. 
Our  objectives  are  beyond  the  capacity  of a  single  research  group  to  achieve. 
However, the collective breadth and combined expertise of our partnership will enable 
us to make substantial progress in a synergistic manner and at an accelerated rate ·of 
success. 
In addition  to  a  detailed  understanding of the  fundamental  mechanisms  regulating  . 
suppression of cancer in normal cells,  one practical benefit of our proposal will be to 
elucidate  the  molecular  mechanism  by  which  schwannomin  is  implicated  in 
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30  %  of all  nervous  system  tumours  that  develop  in  humans.  Based  on  this 
knowledge, it is hoped that new therapeutic approaches may be proposed. 
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HGF  /SF  tyrosine  kinase;  Dictyostelium;  cell  adhesion;  epithelial . 
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Period: 1/5/96-30/4/99  Total EC Contribution : ECU 250,000 
Prostate cancer is ubiquitous world-wide and since the tumour is  associated with the 
ageing process, it is clearly a growing health problem in Europe.  At present we have 
no method of  predicting those patients at risk of  developing malignant decease, and no 
consistent genetic markers have been identified.  Also, no treatment has proven to be 
efficient as soon as  th~ tumour become invasive.  It is therefore of  some importance to 
design a new therapeutically approach using cellular and molecular biology tools.  A 
major  break through may  come from  the development  of a tissue  specific  transfer 
strategy of  "suicide" genes as· a gene therapy.  This approach may allow the treatment 
of {I)  primary  cancer which is  conventionally  treated  by  surgery  allowing  a  better 
recovery in term of impotency and urinary incontinence, and (ii) distant metastasis for 
which no treatment is· effective.  Indeed, the specific targeting of  prostate cells should 
render metastases accessible to therapy for the first time in prostate cancer.  Therefore, 
we have set out to develop a joint research effort within the European Union and 7 
partners  from  France,  GB,  Ireland,  Belgium  and  Italy  have  accepted  to join the 
network.  We believe that such a task force should rapidly establish a leadership in the 
field  where a world-wide competition is developing.  Also,  one of the major aims of 
this research effort is to allow rapid transfer to the clinic, with industrial partnership. 
Three  stages  are  involved  in  development  of human  gene  therapy  and  different 
possibilities  are  available  in  view  of the  complementary  expertise  of the  partners 
associated with the network.  (i)  The transduction by viral vectors or transfection by 
· DNA-mediated systems of appropriate target cells are tools which can be adapted for 
use  by  selection  of properties  useful  in  particular  situations.  Retroviruses  and 
adenoviruses  are  among  those  which  have  been  the  most  widely  used.  (ii)  By 
enhancement of prostate-specific gene expression, in addition to a specificity of gene 
delivery,  we can eliminate  aberrant expression of therapeutic genes in non-prostatic 
target cells.  For this we are developing a set of prostate specific promoters able to 
drive expression of  effector genes.  (iii) The feasibility assessment of different effector 
genes to direct "suicide" or proliferation control of the targeted prostate cancer cells 
has  prompted  us  to  design  parallel  strategies  to  maximise  the  complementary 
expertise's of  the network partners.  Thus, we have focused on gene products which 
are· cytotoxic,  regulate  apoptosis or inhibit proliferation.  To test these  alternatives, 
standardised in vitro and in vivo models are already available or are under development 
within the network. ·  · 
As a result, we expect to improve the quality of the cellular and molecular research 
carried out on prostate cancer with the objectives of  gaining new insights in diagnosis 
and treatment.  By providing a new approach to treat prostate cancer, it should assist 
in a significant improvement for both the patient and the social budget. 
Keywords: Prostate  cancer,  human,  gene  therapy,  viral  delivery  vectors,  prostate 
specific promoters, apoptosis control, proliferation control. 
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Page 30 Title:  Therapeutic potentialities of 3' end modified antisense oligonucleotides 
targeted to codon 12 mutated HA-RAS 
Contract N° :  BMH4-CT96-1439 
Period :1/7/96-30/6/99  Total EC Contribution : ECU 1,000,000 
The present project is a logical pursuit of our BIO:MED-1  programme (CT93-1500). 
During this programme we developed new anti-ras  oligonucleotides.  In the present 
programine we will  carry out the necessary experiments to bring this  new potential 
anti-cancer treatment to the clinic. 
We have shown that antisense oligonucleotides directed to a point mutation in codon 
12 of the Ha-ras mRNA selectively inhibited the proliferation of cells expressing the 
mutated Ha-ras gene.  Tumour growth of these  cells  in  nude  mice  was  markedly 
inhibited  after  subcutaneous  injection  of  antisense  dodecamer  absorbed  to 
nanoparticles. 
The predominant nuclease activity which degrades oligonucleotides intracellularly and 
extracellularly are 3 '-exonucleases.  By attaching short alkyl  chains connected to the 
3  '-position  of antisense  dodecamer,  we have  enhanced  stability  of the  dodecamer . 
towards nucleases and lowered tumour growth inhibition dose by 1  00-fold. 
The discovery of these highly active and  selective oligonucleotide analogues prompts 
us to propose pharmaceutical and medical applications. 
Activated  mutated  Ha-ras  has  been  found  in  several  cancers  including  bladder 
carcinomas.  Oligonucleotides could be instilled intravesically, as an adjuvant therapy, 
in  order to prevent progression or relapse  after endoscopie resection.  Therapeutic 
applications  of antisense  oligonucleotides  to  cancer  treatment  require  information 
concerning the in vivo  behaviour of olignonucleotides.  Therefore, this proposal will 
focus  on  the  in  vivo  evaluation  of Ha-ras  targeted  3 '-end  modified  antisense 
oligonucleotides. 
The proposal contains three main lines of  investigation : 
1.  In  vitro  and  in  vivo  evaluation  of the  efficacy  of antisense  oligonucleotides  : 
Evaluation  of original  modifications  which  could  improve  the  stability  and  the 
uptake of  oligonucleotides.  · 
2.  Pharmacological  studies  :  organ  distribution,  clearance  kinetics  and  toxicity  of 
modified dodeacamers will be studied in mammalians. 
3.  Collection of clinical  samples  and  characterisation  : the  aim  is  to collect bladder 
carcinomas samples exhibiting ras mutation in order to establish primary culture and 
derived  cell  lines.  At  the  same  time·  antisense  oligonucleotide  activity  will  be 
evaluated and clinical trials will be started in the most optimal conditions. 
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In vitro and transgenic animal models for basic research 
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tumour initiation, progression and treatmen.t - Animal models of human 
canl!ers 
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Experimental carcinogenesis has, until recently, relied on the use of animal· models in 
which the tumourgenip process is distantly related to that observed in humans.  More 
recently,  the use of transgenic mice  hemizygous for  a tumour suppressor gene has 
opened new opportunities but has also revealed two limitations : first some of  the most . 
prominent tumours observed in genetically predisposed humans are not observed in the 
corresponding  mice  (retinoblastoma is  not  observed  in  mice  hemizygous  for  Rb ); 
second  for  most_·instances  (with ·the  notable  exception of p53) mice  homozygously 
inactivated for a tumour suppressor gene· are not viable.  We propose to overcome 
these difficulties  by  the development  of a modular transgenic  mouse  system which 
should enable the ~ppearance of defined somatic mutations in a tissue specific manner. 
This system is based on the use of the Cre recombinase which directs .  recombination 
between  two  small  oligonucleotidic  target  sequences  called  Lox.  Recombination 
between two Lox sites  in  a  direct  (head-to-tail)  orientation  causes  excision  of the 
intervening DNA.  This principle can be used· to inactivate a tumour. suppressor by 
inducing the deletion of a critical  exon.  The production of 4  series  of conditional 
mutants which will target either Rb or TP53 or APC or NF2 is proposed.  The use of 
transgenic  constructs in which the  Cre recombinase  is  placed  under ·tissue  specific 
promoters should enable to restrict the Cre expression to a relevant tissue (i.e.  to the 
retina for· a conditional Rb mutant). 
An  additional  degree of sophistication is  proposed. which will enable  to trigger the 
creation of  defined somatic mutation not only in a tissue specific mat;mer but also at a 
time  that  is  decided  by  the  investigator.  This  approach  is  made  possible  by  the 
developrnent of new regulatory systems which restrict transgene  expression in cells 
that  express  an  engineered .  transactivitor  that  is · active  only  in  the· presence  of 
tetracycline.  This further development should· be extremely useful in the analysis of 
tumour progression.  Ultimately, development of  a "two channel" system based on two 
independent  inducers  (i.e.  tetracycline  and  tamoxifen)  and  two  independent 
recombination systems (Cre/Lox and  Flp,  Frt,  a system related. to Cre/Lox found  in 
Saccharomyces Cerevi,siae) should provide excellent flexibility io analyse in detail the 
consequences. of the  occurrence  time  of the  different  mutations  that  contribute  to 
tumour initiation and progression. 
Finally,  the development of an original_ tissue specific model of retroviral insertional 
mutagenesis  eventually  combined. with  the  production  of mouse  strains  that  are 
hemizygous  for  a ·defined .  region  containing  a  putative ·tumour  suppressor  activity 
'should provide an approach to the is_9lation of  new genes involved in the tumourigenic 
process. 
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enable further insight into the basic mechanism of  tumourgenesis.  It will also provide 
animal models of human cancer which will  be useful in  testing the new therapeutic 
protocols (including gene therapy) that will  undoubtedly be proposed in the coming 
years. 
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Predisposition, early diagnosis of cancer, and the earlier 
detection of metastases, including technological procedures 
.and development of molecular and cellular reagents 
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tumours, and pilot vaccination studies with defined antigens 
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Period : 1/1/96 - 31/12/99  Total EC Contribution : ECU 200,000 
At the present time several antigens have been identified that are recognised on human 
tumours by autologous cytolytic T lymphocytes (CTL).·  Many of these antigens are 
encoded by genes that are very selectively expressed by tumour cells.  Therefore, it is 
now reasonable to try to immunise  c~cer patients against such tumour antigens to 
stimulate or to induce tumour rejection responses.  · 
A  first  part of the  project is  the identification of new  tumour rejection  antigens 
. recognised  on human  tumours  by  CTL.  We· intend  to  identify  new  antigens  by 
applying  to other types  of tumours  the  methods  that  were  sucqessfully  used  with 
melanoma antigens.  We will derive CTL clones  ag~st  cell lines derived from renal, 
bladder, head and  neck,  and  cervical carcinomas,  from· lung tumours,  sarcomas,  and 
'leukaemias  ..  After the ·identification of  'the HLA' molecule which present the antigen 
recognised by a given CTL clone, the antigen will  be identified by cloning the gene 
coding for the antigenic peptide, using transfection of  eDNA libraries derived from the 
tumour cells.  Another approach will  involv~ the  elution  of the  antigenic  peptides 
bound to the lll.,A molecules expressed by the tumour cells.  Using a combination of 
chro~atography and  mass  spectrometry, if was possible to identify and to sequence 
.individual  peptides  recognised  by  CTL  clones.  The  third  approach  consists  in 
identifying antigenic peptides that are derived from proteins encoded by genes which 
are known: to be selectively expressed. in tumours.  Candidate peptides that are. able to 
bind to defined HLA molecules will be identified.  Thise peptides will be used in vitro 
to stimulate T lymphocytes from normal individuals  and from  cancer p
1atients.  The 
lytic activity of the responder CTL will be tested on tumour cell ·lines expressing the 
relevant HLA molecule and the gene encoding the antig~nic peptide. 
The second part of  the project consists of attempts to stimulate immune responses of 
cancer patients. against these defined 'tumour antigens.  Several. forms of the antigens 
will be tested, in order to compare their immunogenicity in vivo ..  Small  groups of 
patients,  eligible for such immunisations on the basis of their clinical ·status,  of their 
HLA type and of the expression in their tumour of genes that are known to encode 
antigens, will be vaccinated with peptide alone or peptid·e mixed with adjuvant, or with 
recombinant protein with adjuvant, with irradiated cells expressing the antigen,  with 
naked DNA encoding the antigen, and possibly with adenovirus or vaccinia constructs. 
These  modalities  of immunisation  will  be  concomitantly  evaluated in  mice,  using 
tumour antigen P lA.  For the patients, the efficacy of  immunisation Will be assessed in 
vitro by measuring  specific  CTL 'responses in the blood  and;  whenever possible,  in 
tumour-infiltrating' lymphocytes obtained before and ·after vaccination.  · Histology of 
·available ·tumour biopsies will  be evaluated to define the. nature of the lymphocytes 
infiltrated and,  by· PCR, the repertoire of infiltrating T cells.  -Larger clinical studies, 
with progression of the  disease  as  endpoint,  will  be initiated.· with those forms  of 
antigens which will prove· to. generate CTL responses in  a significant proportion of 
patients. 
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Effectiveness of systemic treatment modalities, including 
cytotoxic agents and biological response modifiers as well as 
newer approaches such as gene therapy 
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. therapy 
Contract N° :  BMH4-CT-0638 
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The aim of this  concerted action is to bring  together the intellectual  and_  technical 
resources. of 14  research groups within Europe to  develop· methods by which the 
patients, most at risk, ofradiothenipy complications can be identified.  The success of 
curative radiotherapy ~epends critically on those patients who are most at risk of  dose-
limiting complications.  At the present time,  the standard approach for .  radiotherapy 
with  curative·  intent  is  to  prescribe  the  maximijm  dose  that  is  judged  by  the 
radiotherapist to be.within the limit of  normal-tissue tolerance.  This dose is chosen on 
the basis of  clinical experience to be one that will not lead to serious complications in 
more than a few percent of cases.  This project foreshadows· an important change in 
the strategy of radiation therapy : the individualisation of  dose prescription.  Tissue 
'and  blood· specimens  will  be taken before  treatment  begins  and  subjected  in  the 
laboratory to a series of  tests aimed at achieving the best possible prediction of  normal-
tissue tolerance to radiation therapy.  On the basis of  these tests we aim to identify that 
sub-group of  patients who are most at risk of  damage.  Two· principal options will then 
become available ~o improve patient management : to reduce the intensity of  treatment 
for the patients who are most · at risk  of damage,  and  to increase the intensity of 
treatment for the majority of patients, thereby increasing their likelihood of achieving 
local tumour control. 
Patients who suffer complications of  radiotherapy fall into 3 groups : those who show 
a severe early reaction to irradiation; those who show a level of  late radiation damage 
that stands out as being excessive; and those who suffer early tissue effects that are so 
severe that treatment has to be  curtailed.  The first  2  categories represent patients 
whose sensitivity to radiation treatment is in the upper part of  the normal range.  These 
are  the  patients  whose  reactions  limit  the  dose  of radiation  that  can  be  given. 
Depending upon the tumour site (and·therefore on. the normal tissues at risk) they may 
amount to 2 - 5% of  patients given radiotherapy ·with curative intent.  Within Europe 
they could thus amount to approximately 3,  400 to 8, 4000 patients per year. 
The specific objectives include the following : 
•  To ·establish a standardised experimental. basis for the inter-comparison of results 
from the participating laboratories. 
•  To  provide  an  agreed  classification  of patients'  normal  tissue  responses  to 
radiotherapy. 
•  To establish the range of individual cellular radiosensitivity and its relationship to · 
the variation of  normal-tissue response to radiatherapy. 
•  To evaluate and establish the reproducibility and accuracy of  rapid assays of  cellular 
radiosensitivity that may be applicable for clinical predictive assays of  normal-tissue 
radiosensitivity. 
•  To •agree methods of clinical evaluation of predictive assays tests of normal-tissue 
response prior to the introduction of  prospective clinical trials  . 
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to  significant  improvements  in  health  care.  Firstly,  it  will  reduce  the  serious 
complications of radiotherapy which are a burden· not only to the individual patients 
but also have significant cost implications for the health-care system.  Secondly, it may 
lead to improved management of the majority of patients by increasing local tumour 
control. 
Key Words :  Predictive testing, radiosensitivity, normal-tissue damage, DNA and 
chromosome damage, cell-cycle effects. 
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Period: 1/1/96- 30/12/98  Total EC Contribution : ECU 400,000 
Several genes have been identified which strongly predispose to breast cancer, giving· 
rise ·to high-risk families.  The two_ most salient ones are BRCAI  on 17 q 12-q21,  and 
BRCA2 on 13ql2-ql3.  The gene sequence of BRCA1  was recently elucidated and 
direct mutation screel).ing is now feasible.  BRCA2 has not yet been isolated,  but its 
location on chromosome 13 is accurately defined by polymorphic DNA markers.  The 
main objective of  this proposal for a Concerted Action is to generate large well-defined 
data  sets  by  means  of specific  data  calls,  which  are  powerful  enough  to  address 
important questions in relation to gene mapping, genetic heterogeneity, the spectrum 
of cancer  risks  associated  with  different  mutations,  the  effect  of programmes  of 
intervention for  individuals  at  risk,  and  the  use  of genetic  data  from  tumours  for 
prognosis and management of  patients. 
We expect to have assessed the genetic basis of the breast cancer predisposition in at 
least 350 families (250 BRCA1;  100 BRCA2).  For BRCA1, this will allow the study 
of genotype-phenotype  correlation's,  and  mutation-type  specific  cancer  risks.  For 
BRCA2,  associated cancer risks  and  penetrance can be  estimated.  In the cohort of 
carrier women, the effect of known risk factors for breast cancer,  such as parity and 
age at menarche, will be evaluated.  In an attempt to identify genetic modifiers of the 
risk, polymorphism association studies will be performed in this cohort for a number of 
candidate genes.  To investigate whether inherited  breast cancer is  a distinct  entity 
relative to non-familial  breast cancer,  various  somatic genetic  changes,  which occur 
frequently  in  sporadic  breast tumours,  will  be  characterised  in  at  least  300  breast 
tumours from BRCA1- and BRCA2-linked families.  In addition, their histopathology 
as well as several prognostic factors will be compared with sporadic breast cancer.  We 
expect to identify  a number of high-risk families  that  are not linked  to BRCA1  or 
BRCA2, which will be employed to localise BRCA3. 
EUROBCLC will maintain a database of  studies of  population-based series conducted 
by the Consortium members.  Systematic studies will be undertaken to determine the 
prevalence  of BRCA12-mutations  among  defined  clusters  of breast  cancer,  e.g., 
among 2,500 women unselected for family  history  and  200  sister-sister,  or mother-
daughter pairs. 
Finally, at EUROBCLC-meetings, experiences related to social, psychological, ethical, 
and organisational aspects of  predictive gene testing for BRCA1  (and later, BRCA2), 
will be exchanged.  Possibly this will lead to the formulation of specific projects once 
genetic testing is underway in  a number of countries.  We can already envisage for 
example, the collation of data about ·- provision of genetic services, uptake of genetic 
testing, management of  individuals at risk - which will almost certainly differ markedly 
between countries. 
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The major focus of  this study will be to collect families with (a} three or more prostatic 
cancer. cases diagnosed at any age;  or (b) two .  or more .  affected brothers diagnosed 
before the age of 65  years.  . Such ·families  are candidates for carrying an inherited 
susceptibility predisp'?sing to prostatic and possibly other malignancies.  The families 
will be collected through major clinical urology centres· through Europe.  This bank of 
materi~ both DNA and RNA, will then be available for molecular genetic studies to 
identify genes predisposing to prostate cancer.  . The project will. initially use genetic 
linkage analysis to identify genes which contribute to the risk of  prostate cancer and to 
assess  the importance of this  gene/these  genes· to familial  prostate  cancer.  DNA 
markers which are usually based on· microsatellite repeats and which· are  known to 
have high degrees of polymorphism are typed within the families  and tested for co-
segregation with the putative prostate cancer susceptibility gene.  Evidence for co-
segregation is ·assessed statistically.  The analysis will focus on a variety of.candidate 
genes which are known to play a role in either prostate -development or in other cancer 
susceptibility syndromes such as those for the breast cancer syndromes, BRCA1  and 
BRCA2.  Only  in the event that none .  of diese tum· out to be important would  a 
genome-wide mapping search be initiated.  When a· gene or more probably a genetic 
region is identified as being important, we will assess the importance of  this region to 
f8milial prostate cancer. 
The other approach will be to examine the importance of  genes thought to modify the 
risk  of prostate  cancer .. using  a  case-control  approach.  We will  collaborate with 
ongoing studies which are investigating environmental  causes of prostate cancer to 
examine .  the  role  of gene-environment  interactions  in  determining  prostate  cancer 
susceptibility. 
Keywords:· Prostate  Cancer,  linkage  analysis,  familial,  inherited.  susceptibility, 
mapping, gene-environment interaction, mutation. 
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the prostate 
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This  proposal  focuses  on  diagnostic  issues  directly  related  to  the  selection  and 
outcome of appropriate treatment regimens aimed' at increasing the· survival ,rates  of 
prostate cancer (PC) patients.  We intend to : 
1.  Construct  highly · sensitive  and  specific  techniques  to  iptprove  the  early,  cost 
effective detection of  aggressive, organ confined and curable PC. 
2.  Construct  sensitive  ·and  specific  techniques .  that  at  an  early  phase  can  detect 
micro  metastatic dissemination of  the tumour in the blood circulation. 
3.  Identify  molecular  markers  in  tissue  and  blood  to  distinguish  aggressive  life-
threatening cancers from non-aggressive, latent tumour lesions. 
The proposed research goals are distinct,  though relevant to those of the European 
Randomised study of  Screening for Prostate Cancer (ERSPC) supported by EC grants. 
The  interactive  programme  involves  5  established  European research  groups  (four 
academic and one from the industry) with long-term records of successfully combining 
fundamental,  applied  and  clinical  research.  Two  groups  are  from  the Netherlands 
(Rotterdam,  Nijmegen),  one  group  from  Sweden  (Malmo)  and  two  groups  from 
Finland  (Tur~).  The three clinical  centres co-operate in prospective  colle~ion. and 
analyses of tissue and  blood specimens from patients and  controls.  A retrospective 
material with follow-up  data is obtained from the ERSPC pilot study in Rotterdam : 
.... 400 PC patients and -1700 control subjects.  The number of  prospectively diagnosed 
cases of  PC from the three clinical study sites will be -600 patients per year. 
·The research goals are : 
1.  To design sensitive,. specific and standardised methods for the early detection of  PC 
by(i) .constructing assays for multiple forms of  PSA and glandular· kallikrein (hK2) 
in  serum,  (ii)  analysing  collected  sera  at  three  clinical  sites,  (iii)  comparing  the 
obtained  data·  with  those  of presently  available  test  (total  PSA,  digital  rectal 
examination. (DRE)  and  transrectal  ultrasonography)  in  order  to  evaluate their 
clinical utility and to reduce the number of  unnecessary biopsies. 
2.  To design sensitive, specific and  standardised .techniques to distinguish aggressive 
from non-aggressive and  possibly  also  organ confined from metastatic PC by  (I) 
detecting specific mRNAs for PSA, hK2, .prostate specific membrane antigen and 
the androgen· receptor from micrometastatic cells in the blood, (ii) evaluating· these 
techniques clinically.  -
3. ·.To study. tissue, parameters that may distinguish aggressive from non-aggressive PC 
by  :  (I)  developing  standardised  procedures  for  morphometric  analysis  and 
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cytochemical detection of tissue markers,  and by (ii) evaluating the data from the 
developed procedures with clinical data. 
Keybords:  Prostate cancer, early detection, aggressiveness index, circulating cancer 
cells,  PCR detection, prognostic factors tissue, morphometry, PSA free 
and bound, human glandular kallikrein and tissue markers. 
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Organ transplantation is  followed.  by  an· increased  risk  for  development of cancer. 
Analyses  of materials  from  transplanted  and  therefore  inimunosuppressed  patients 
allow  the  possibility  to  find  risk  factors  for.  cancer  and  to  evaluate  oncogenetic 
mechanisms in general. 
.  ' 
In our most recent analyses performed using correct cancer epidemiological methods 
an increased incidence of 3  · - 5 times that in the general population has been found, 
including most types of tumours, however with an uneven pattern with emphasis .  on 
lip  ..  cervical-,  wlvar-,  urological-,  skin-cancers  and  lymphoproliferative  disorders 
(PTLD}  Most tumours occur early (include. PTLD) after transplantation, tumours of 
the skin however later and with an increase with time. 
This  complication  appears  to  be  increasing  in  degree  for  all  types  of  organ 
transplantation, however a parallel increase in our. knowledge concerning possible risk 
factors and oncogenetic mechanisms in general.  Many of the tumours appear to be 
associated  in  some  way  with  virus  infections,  thus  opening  up  for  possible  new 
approaches to prophylaxis and treatment. 
Based on previous cancer epidemiological studies in the Nordic countries it is the aim 
of  this new study to : 
1.  perform a follow-up on existing files on kidney transplanted patients in the Nordic 
countries to latest possible date in  the framework  of  ·  Scandiotransplant  and  the 
Association of  the Nordic cancer Registries 
2.  to analyse the Nordic material concerning all types of  organ transplantation to latest 
possible  date in  the framework  of Scandiatransplant and  the Association of the 
Nordic Cancer Registries (ANCR) 
3.  to  start  a  prospective  registry  with  extensive  use  of existing  data  files  in  the 
Scandiatransplant organisation and the Association of  the Nordic Cancer Registries 
(ANCR) allowing yearly analysis,  with  1-3  in a  collaborative study including  all· 
_Nordic transplantation centres and cancer registries 
4.  to perform a  study. of cancer in· patients on dialysis in the European Institute of 
Oncology, Division of Epidemiology and Biostatistics. in Milano,  Italy, which co-
operates with centres in many European countries,.· since this will be complementary 
. to the transplant study, as these patients are uremic. with depressed immune defence, 
however not transplanted and immunosuppressed by drugs. 
The cancer epidemiological analysis will  allow identification of cases to. be analysed 
intensively in : 
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(DK), and tissue typing (DK, FI, N, SE) 
6.  identified cases with proved Epstein-Barr oncogenetic background will be treated 
with a  combination of (a) intravenous  high-dose  aciclovir  and  (b)  decreased  or 
discontinued immunosuppression. 
The overall aim is to bring together cancer epidemiology (in the Nordic countries and 
Italy)  with .new  advances  in  cellular,  molecular  and  developmental  genetics  in 
immunopathology and immunology (  cytokines and tissue types) and virology in order 
to obtain new biologi~al insights and improvements in both diagnosis and treatment of 
interest for  the field  of transplantation  and  thereby  also  to  obtain  new insights  in 
oncogenesis per se. 
Keywords:  Cancer,  transplantation,  immunosuppression,  dialysis,  cancer-
epidemiology,  immunopathology,  virology,  Epstein-Barr  Virus, 
cytokines, tissue typing 
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Period : 1/7/96 - 30/6/99  Total EC Contribution : ECU 129,929 
The  European  Randomised  Trial  of Ovarian  Cancer  Screening  (ERTOCS)  was 
awarded  a research  contract with the European Commission as  a  concerted  action 
project under the Biomedical and  Health Research Programme (Biomed  1)  in  1993 
(Contract No.  B:MHI:-CT93-1741).  The project is a multicentre randomised. trial of 
ovarian cancer screening  usi~g ultrasound  examination of the ovaries.  This project 
seems to provide a network resource under Reinforced Concertation for an integrated 
ultrasound screening management system that will combine two basic elements, (I) the 
capture  and  storage  of digitised  ultrasound  images  from  the  trial  using  new high-
density CD-ROM storage technology and, (ii) interactive software linking the digitised 
ultrasound images with administrative and clinical data, follow-up details of  cancer and 
death, and freezer locations of samples stored in the biological specimen bank (serum 
for  tumour  markers  and  whole  blood  for  DNA studies).  This  will  be  a  valuable 
technical aid in providing the specialised quality control needed for the management of 
the trial.  This network resource will contain all the data (ultrasound images,  clinical 
data and  biological  samples) in one electronic system.  Although serum banking for 
epidemiological studies is not new, storage of  ultrasound images has not been done in 
this way before and  will provide a unique  system for quality control in imagine  and 
monitoring ultrasound screening programmes.  For example,  a screening test can be 
judged to be positive on the volume of  the ovary as measured by the ultrasonographer. 
Readings  that are  consistently too high will  result in  too high  a false  positive rate. 
Images cannot normally. be retrieved so whether or not the reading accounts for the 
false positive rate cannot be determined retrospectively.  With this system the images 
can  be  retrieved  and  evaluated  providing  quality  assurance  in imaging  techniques 
ultrasound screening programmes can be objectively monitored.  In addition, if a case 
of  ovarian cancer were missed by screening, it would be possible to identify and locate 
the relevant stored serum samples and ultrasound images and  retrieve them to see if 
the cancer might have been detected much like a pathologist might retrieve a slide for 
review after a missed diagnosis. 
The proposed system permits examination of all trial data at the co-ordinating centre 
on a monthly basis  so  that if problems emerge there can be rapid feedback  to local 
centres.  This system offers, in one package, trial management and  quality assurance 
that previously could not be achieved.  It will also provide a bank of images,  normal 
and abnormal, that can be used as a teaching package for ultrasonographers involved in 
ovarian cancer screening. 
Keywords·:  Ovarian  cancer,  screening,  ultrasound,  imaging,  randomised  trial, 
storage, sample banks, database. 
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Period : tn  /96 - 30/6/99  Total EC Contribution : ECU 690,000 
The principal limitations  of allegoric  bone marrow transplantation (ABMT)  are the 
lack ofsuitable HLA-matched donors for the majority of  patients and the complication 
of graft-versus-host disease (GvHD).  The _lack  of sibling  donors in some cases has 
been overcome through the establishment of  large panels of potential marrow donors 
but these panels ·are .  restricted  in  terms  of HLA polymorphism  and  of·  their  ethnic 
diversity.  This  is  most  marked  in  Europe where ·  each  nation  has  its  own  ethnic 
diversity.  Limitation is also. related to the. fa~ that results of allegoric bone marrow 
transplantation from normal bone marrow donor are dependent of  HLA-A, B, C, DR, 
DP,  DQ  identity  between  donor  and  recipient.  Umbilical  cords  from  full-term 
pregnancies have been shown to be a source ofhaematopoetic progenitors (1,2,3,5,6). 
Banks of cord blood samples are being established in a number of  EU member states 
(47).  A number  of cord blood transplants  have  been performed  with encouraging 
results (3,39,40,41,42,43,44).  Preliminary evidence suggests that these transplants are 
associated with less GvHD than comparable unrelated BMT. 
The  purpose  of the  research  is  to  advance  our  understanding  of cord  blood 
transplantation and to establish common criteria and protocols for the handling of  cord 
blood samples. 
1.  Objectives 
- to standardise the methods of  collection, testing and cryopreservation of  cord blood 
- to .study the properties of  haematopoietic progenitors present in cord blood 
- to study the immune function of  cord blood lymphocytes 
- to co-ordinate and facilitate the exchange of sera and cells from regional cord· blood 
depositories held in member states 
- to establish a Eurppean Registry of  patients treated by cord blood transplantation and 
design  protocols  comparing  cord  blood  transplants  with  alternative  conventional 
blood and bone marrow haematopoietic stem cell transplants. 
2.  Overview 
The  concerted  action  (  CA)  will  :  1)  compare  methods  of collection,  banking  and 
testing of cord blood collected for clinical use across  different  European countries. 
This  will  need  communication between obstetricians,  blood  banks  and  laboratories 
involved in cellular biology, microbiology,  immunology and. the .detection of genetic 
disease ; 2) study the properties of haematopoietic stem cells  present in cord blood 
with regard to their selection and expansion for the purpose of improving their long 
term  capacity  for  engraftment  ;  3)  study .. the . immune  reactivity · of cord  blood 
lymphocytes.  The T lymphocytes ~d  natural killer cell subsets present in cord blood 
samples will  be characterised.  Their in vitro  responses  to mitogenic .and  antigenic 
stimulation will be measured to·. determine functional maturity as will their reactivity to 
allegoric  stimulation  (GvHD)  and· to  leukaemia  cells  (GvL)  ;  4)  co-ordinate  the 
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to  perfect  the  detection  and  enumeration  of contaminating  maternal  cells  ;  study 
transmission of  infectious diseases from the mother to the child and perform studies of 
transmission of genetic diseases ; 5) establish a central registry of all European cord 
blood transplants to facilitate the analysis of results.  Subsequently to design trans-
European clinical studies in the light of  these analyses. 
The significance of this application is that the research planned herein is  beyond the 
capability of any  single  EU member  state.  This  research will  be done within the 
European Blood and Marrow transplant group.  All members of  the project are active 
members of  this group.  This project has been approved by the board of the EBMT. 
(March,  13  1995)  Co-operation and  exchange  of ideas,  material  and  personnel for 
training will allow the successful· completion of  these studies and the transfer of  many 
expert techniques to EU states with less well-developed medical research facilities . 
. Keywords: Cord blood, immunobiology,  haematopoietic stem cells,  transplantation, 
GvHD, GVL, BMT. 
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:  -
Myelodysplastic Syndromes (MDS) form a group of blood cell-disorders, with high 
risk for development of  secondary Acute Myeloid Leukaemia.  The number of  patients 
are 'increasingly being treated with intensive  anti-leuk~emia therapy.  Generally,  the 
treatment effects  ar~ i.nferior to-those obtained in primary leukaemia.  European-wide 
clinical  evaluation- of this  new  treatment  modality  was  started  in  1993  within  the 
framework of  the EORTC and the EBMT  .. 
In the present BIOMED 2 project_the co-operating research groups carry out an in-
depth study to elucidate the underlying molecular and genetic mechanisnis of MDS-
pathogenesis,  and  of MDS-treatment. _ Analysis  of the  nature  of r_emission  and 
monitoring of residual  disease is thought to be essential-for  rational  application of 
-~intensive, and  expensive myelotoxic treatment of_MDS  or s-AML.  Especially,  the _ 
question is emphasised to which extent intensive chemotherapy or autologous stem cell 
transplantation induces  cytogenetic  and  polyclonal  remission.  This  knowledge  will 
. enable to predict impact of the treatment on the duration of polyclonal remissio~ and 
on the prognosis  of the  patients.  As  a  consequence  an  objective  instrument  will 
become available. to support the clinical decision process leaaing to a treatment policy 
in which expected outcome for the patient is considered. 
Qualitative Objectives Concern : 
•  Assessment  of  efficacy  and  effectiveness  of  intensive  antileukaemic  therapy 
(cytogenetic and clonal remission, clinical response, survival ~d  costs) 
• . Standardisation  and  quality  control  of  molecular  techniques  in  malignant 
haematology,  with special  emphasis  on Fluorescent In Situ  Hybridisation (FISH) 
and Polymerase Chain Reaction (PCR). 
•  Promotion of  vital links between basic research and clinical studies. 
The study· includes patients, already participating in a recently started European study. 
FISH  and  molecular  analysis  of blood  and  bone  marrow  samples  will  provide 
evaluation of monoclonal  versus  polyclonal  remission.  Cell  populations of female 
MDS patients with and without the characteristic cytogenetic markers will be- asses~ed 
for clonality by x  ... chromosome inactivation patterns.  During the project period an. 
intensive  quality  assessment  programme  is  etcecuted  in  order  to  assure  high 
comparability of  results obtained in different laboratories. 
The project will provide knowledge concerning the molecular mechanisms ofMDS.  It 
will  increase access to sophisticated laboratory techniques for  a  number of clinical 
institutes.  Moreover, it  will contribute to improvement of  the medical decision. process 
concerning alternative_ treatment strategies in malignant haematology,  especially with 
regard to :MDS. 
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The objectives of EuroDeucaTam Project are to evaluate the potential carcinogenic 
risks linked to several treatment modalities· for breast cancer.  In particular, the study 
will quantify any increases in· selected second cancers following breast cancer.  For the 
period  1996-1998,  th~ study will concentrate on cancers of  the endometrium,  ovary 
and  liver  following  breast  cancer.  It  will  determine  the  ·etiological  role · of all 
reproductive  variables,  other variables known ·to  be  associated with risk  of breast 
cancer and  of the other tumour under study,  and  of primordial interest will' be the 
assessment _of the effect of  the various treatment modalities of  breast cancer (surgery, 
radiotherapy,  chemotherapy and. hormonotherapy).  The main  exposU;re under study 
will be  tamoxifen,  with a  detaileg  evaluation· of  the  effects  on risk  of daily  dose, 
duration  of tr-eatment  and  the  interaction  with  other  treatments  radiotherapy, 
chemotherapy, and castration with evaluation of its effects according· to method· used 
(radiotherapy versus surgery). 
The methodology used will be that of case-control studies.  The cases will be women . 
developing the second cancer of  interest after having had breast cancer.  Breast cancer 
diagnosis  should have been tnade after the introduction of tamoxifen in the country 
concerned .(1976).  The source of cases on referents will be population-based cancer 
reg1~tries (to avoid biased ascertainment of cases and ·referents).  The two diagnoses 
(breast cancer and second cancer) will have been recorded· by the participating cancer 
registries.  There will be four controls for every case.  The~e  will be women diagnosed 
with breast cancer at the same time· and in the same registry as. the case.  ·They will be 
·matched for age(± 2 years) and date ·of breast cancer diagnosis (± 2.years) with the 
case.  They will .have survived at least until the date of diagnosis of  the .case, and for 
· controls of endometrial cases, not having at that date undergone a  hyst~rectomy~ and 
for controls of ovarian cancers, not having  at that date undergone an ovariectomy. 
The source of  information on exposure will be the 'cancer registry files. and the clinical 
records with no persqnal interview of  the women themselves.-
This  study will  provide useful information on the long-term safety  of breast cancer 
treatment.  In addition,  tamoxifen,  a synthetic antioestrogen which 'has  be~n widely 
used for the treatment of  breast cancer and has· been shown to be effective. in reducing 
overall  mortality  as  well  as  mortality  from  breast  cancer. and  the  occurrence  of 
contralateral breast cancer is being proposed for the prevention ofbreast cancer among 
healthy .women considered to be at high risk of developing breast ·cancer.  Preventive 
trials are now underway hoth in the USA and in Europe.  Nevertheless, concerns have 
been  raised  with  regard  to  the  side  effects  ·of tamoxifen  and  in  particular  the 
carcinogenicity of  this product.  This study will help to answer these concerns. 
Keywords:.  breast  cancer,  castration,  chemotherapy,  endometrial  cancer, 
epidemiology, liver cancer, ovarian cancer, tamoxifen:· 
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Title : · . Meta-analyses for the improved treatment of  cancer 
Contract N° :  BMH4-CT96-0019 
Period : 1/5/96 .;.· 30/4/99  Total EC Contribution : ECU 300,000 
The major aims of  the European Organisation for Research and Treatment of Cancer 
(EORTC), which involves the participation of more than 300 European institutions, 
include the co-ordination of research in' Europe on cancer ·treatment~. the linking of 
clinical practice to ongoing basic research,  and the dissemination of state of the art 
knowledge in oncology among hospitals and clinician& in Europe. 
As numerous. publications have shown, it is well. known that many clinical trials include 
too few patients in ord~r to be able to. reliably detect small to moderate (but medically 
important) 'treatment differences.  Given that many ·small, inconclusive trials exist, the 
best w~y  to combine together and objectively summarise the results from trials that ask 
similar questions is through the technique of  meta-analyses. (overviews).  Meta-analysis 
is the process of  using formal statistical methods to combine the quantitative results of 
separate but similar studies in order to increase the statistical precision of  the estimated 
treatment effects.  Meta-analyses provide clinicians, patients and policy markers with · 
reliable, objective evidence on the effects of  health care in order for professionals and 
providers, service· users and purchasers, and researchers and funders to be able to set 
priorities and establish resources for both medical research and patient treatment.  In 
this way truly informed decisiqns can be made concerning the potet;ttial impact· of new 
therapies in clinical practice. 
With the support from the European Commission through BIOl\1ED 1,  the EORTC 
Data Centre established a Meta-Analysis Co-ordination Unit (EORTC MAU) in May 
1994.  This has provided the EORTC with the scientific means and expertise required 
to identify, process and analyse the individual patient data from trials to. be included.in 
meta-analyses which are conducted by the unit.· It also co-ordinates and provides data 
for  patients  entered  in  EORTC  trials  to  be  included  in  meta-analysis  projects 
undertaken  by  other  groups.  Creation  of this  Unit  has  provided  the  means  to 
successfully increase the contacts and  co-ordination of meta-analysis  activities  with 
other· centres such as the Medical Research Council (MRC) Clinical  Trials Services 
Unit in Oxford,  Great Britain, and the MRC Cancer Trials Office in Cambridge, Great 
Britain with  ·~hom  joint projects exist.  · 
The succ~ss of  the work already accomplished by the EORTC MAU forms the basis of 
this grant submission which builds upon and extends the work of  the MAU which was 
funded  through  BIOMED  1  for  the  period  from  May  1994  to  April  1996.  In 
particular,  a  continuation of meta-analysis projects in  acute mylogenous leukaemia, 
superficial bladder cancer and early breast cancer is sought (in order to allow for their 
:up-dating,  an  essential  requirement  to ·ensure  conclusive  results)  along  with  the · 
creation of  new projects in malignant melanoma, soft tissue sarcoma, locally advanced 
head and neck cancer, and locally advanced cervical cancer.  These are other types of 
cancer for which many trials have been carried out, but with inconclusive results and 
for which meta-analyses are therefore important.  · 
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rapidly  as  possible  with  the  European  Co~unity, it  will  be  possible  to  further 
improve the treatment and  management of cancer in Europe.  In this way as many 
patients  as  possible  will  profit from  state of the  art treatment,  even those  treated 
outside of  research oriented institutes. 
A reinforced concerted action is  being requested in order to permit the training of 
scientists in the conduct of meta-analyses,  thus allowing the further dissemination of 
this technology within the Member States. 
Keywords :  meta-.analysis,  randomised  clinical trials; cancer treatment,  individual 
patient data, dissemination of  results, training. 
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prospective evaluation ·of my¢1oablative radio-chemotherapy with .blood 
stem cell transplanatation 
Contract N° ':  BMH4-C1;96-1539 
Period : 1n  /96 - 30/6/99  Total EC Funding: ECU 150,941 
Mantle  lymphomas  (MCL)  represent  a  recently  recognised  sub-type  of malignant 
lymphomas which are charaterised by a specific histology and immunophtmotype and 
an unfavourable clinic.al course.  Hence, response to chemotherapy is poor arid. pat~ents 
with this disease usually face a median survival of less than three years.  The recent 
discovery  that  MCL  are associated  with  a  specific  chromosomal  abnormality,  the 
translocation t ( 11; 14) that leads to the deregulation of  cyclin D 1 and over-expression 
of bel  1  and  a  consecutive  impairm:ent  of cell  cycle  control  has  opened  ·new 
perspectives to better understand the biology of  this lymphoma and also potentially its 
clinical course.  The current multinational study .  aims at gaining new insights into the 
biology of  MCL and its appropriate clinical management and  tri~s to explore a novel 
· therapeutic  strategy  comprising  myeloablative  radio-chemotherapy  with  subsequent 
peripheral blood  stem cell transplantation.  These  objectives  are addressed in three' 
·  major steps : 
•  The assessment of  clinical and histopathologic  .. features. of  presentation as obtained 
from a retrospective analysis· of  pati~nts that have been treated· with conventional 
therapies at the participating inst~tutions; _ 
•  The biologic characterisation of  MCL by means of  modem immunophenotypic and 
molecular techniques; 
•  The prospective evaluation of myeloablative radio-chemotherapy with subsequent 
blood stem cell transplantation. 
Keywords :  Mantle  cell  lymphoma,  blood  stem  cell  transplantation,  cytogenetics, 
cell kinetics, molecular aberrations, quality control 
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